

# Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight

## Co-Moderators:

- Rick Winneker, PhD, Senior Vice President, Research, Leukemia & Lymphoma Society
- Mike Rice, Senior Consultant, Defined Health

## Panelists:

- Brian J. Druker, MD, Director, OHSU Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, Oregon Health & Science University, Investigator, Howard Hughes Medical Institute
- Eric Hedrick, MD, Chief Medical Officer, Epizyme, Inc.
- Omar Abdel-Wahab, MD, Assistant Member, Memorial Sloan Kettering Cancer Center
- Nicholas J. Sarlis, MD, PhD, Vice President & Head, Medical Affairs, Incyte Corporation
- Scott Biller, PhD, Chief Scientific Officer, Agios Pharmaceuticals




**CANCER**  
**PROGRESS**  
*by Defined Health*

# What is Needed for Successful Targeted Therapy in AML?


- Comprehensive understanding of molecular pathogenetic events or signaling pathways required for growth and survival
- Full arsenal of targeted agents
- Complete understanding of resistance mechanisms
- Ability to match the right patient with the right drug(s)

# AML is Incredibly Heterogeneous

90% exhibit hypersensitivity to at least 1 drug



# Accelerated Progress by Integrating Genomic and Functional Data



# Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight

## Co-Moderators:

- Rick Winneker, PhD, Senior Vice President, Research, Leukemia & Lymphoma Society
- Mike Rice, Senior Consultant, Defined Health

## Panelists:

- Brian J. Druker, MD, Director, OHSU Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, Oregon Health & Science University, Investigator, Howard Hughes Medical Institute
- Eric Hedrick, MD, Chief Medical Officer, Epizyme, Inc.
- Omar Abdel-Wahab, MD, Assistant Member, Memorial Sloan Kettering Cancer Center
- Nicholas J. Sarlis, MD, PhD, Vice President & Head, Medical Affairs, Incyte Corporation
- Scott Biller, PhD, Chief Scientific Officer, Agios Pharmaceuticals



**CANCER**  
**PROGRESS**  
*by Defined Health*